Excerpt from Healio:
“An online prognostic tool accurately determined the risk for late distant recurrence among women with ER-positive breast cancer, according to a single-arm, prospective study.
“The Clinical Treatment Score post-5 years (CTS5) tool could be used to determine whether patients should continue endocrine therapy 5 years after initial treatment.”
Go to full article published by Healio on Sep 19, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.